**BACKGROUND**

- The National Psoriasis Foundation (NPF) has defined treatment goals to improve patient care in psoriasis.
- The goals establish targets to inform treatment decisions, reduce disease burden, and improve patient outcomes in clinical practice.
- The real-world effectiveness of ixekizumab, a highly selective IL-17A monoclonal antibody, has been evaluated in patients with moderate-to-severe psoriasis in the Taatz Customer Support Program (CSP).

**OBJECTIVE**

To evaluate the real-world effectiveness of patients initiating ixekizumab to achieve NPF-defined treat-to-target goals after 12 weeks of treatment with data from the CSP.

**METHODS**

US Ixekizumab CSP Design

- **Patient Population**:
  - Psoriasis patients initiating ixekizumab in the US Ixekizumab CSP design from January 2018 to December 2021.
  - Participants initiated treatment with ixekizumab between January 2018 and December 2021.

- **Assessment**:
  - Clinical assessments at baseline, Weeks 2, 4, 8, 12, and 24.
  - Patient-reported outcomes using internet-accessible questionnaires.
  - Duration from onset of psoriasis, months.

**ABBRVIATIONS**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSA</td>
<td>Body surface area (% of body)</td>
</tr>
<tr>
<td>DLQI</td>
<td>Dermatology Life Quality Index</td>
</tr>
<tr>
<td>NPF</td>
<td>National Psoriasis Foundation</td>
</tr>
<tr>
<td>PsO</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>PsA</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>IXE</td>
<td>Ixekizumab</td>
</tr>
<tr>
<td>NRS</td>
<td>Numeric rating scale</td>
</tr>
<tr>
<td>PatGA</td>
<td>Patient’s Global Assessment</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
</tbody>
</table>

**RESULTS**

- **Target BSA ≤1%**
  - 100% response (N=136)
  - 90% response (N=167)
  - 80% response (N=213)

- **Acceptable BSA ≤25% improvement from baseline**
  - 100% response (N=213)
  - 90% response (N=167)
  - 80% response (N=136)

**CONCLUSIONS**

- The results from this study provide evidence of the real-world effectiveness of ixekizumab; observations from the overall sample were similar to those across the subgroups, PsA and biologic use.

**ACKNOWLEDGMENTS**


**REFERENCES**


**DISCUSSION**

- Although BSA was measured differently (patient vs. clinical assessment) the findings for target and acceptable responses in this real-world study were similar to those seen in the UNCOVER Phase III clinical trials.
- With a real-world study population, factors influencing outcomes may also include, but are not limited to, compliance with medications, and experience with biologic treatments.